Rapamycin & Longevity
The mTOR Inhibitor Extending Lifespan in Every Species Tested
Rapamycin (sirolimus) is the only compound shown to extend maximum lifespan in mammals. Originally an immunosuppressant, low-dose intermittent protocols are now being studied for geroprotection.
The mTOR Pathway
mTOR (mechanistic target of rapamycin) is the master switch between cellular growth and cellular maintenance. Rapamycin tips the balance toward repair.
mTOR Active
Growth mode: cell division, protein synthesis, nutrient storage. Essential during development, problematic when chronically elevated in aging.
mTOR Inhibited
Maintenance mode: autophagy activated, damaged proteins cleared, mitochondria recycled. The cellular spring-cleaning that slows aging.
The Evidence
Rapamycin extends lifespan in yeast, worms, flies, and mice. In the ITP mouse study, it extended median lifespan by 9-14% even when started late in life.
Clinical Research Highlights
Human trials are showing promising results for immune rejuvenation and age-related disease prevention.
Immune Rejuvenation (Mannick 2018)
Low-dose mTOR inhibition in elderly adults improved flu vaccine response by 20% and reduced infections. The immune system functioned as if years younger.
Periodontal Health (Hoang 2020)
Topical rapamycin reduced gum inflammation and bone loss markers in elderly patients. Oral health is a key biomarker of biological aging.
PEARL Trial (Ongoing)
The first large-scale placebo-controlled trial testing weekly rapamycin (5mg) in healthy older adults, measuring comprehensive aging biomarkers.
Dosing Protocols & Safety
The longevity dosing paradigm is fundamentally different from immunosuppressive dosing.
Rapamycin is a prescription medication. This page summarizes published research and does not constitute medical advice. Consult a qualified healthcare provider before considering any rapamycin protocol.